High-dose intravenous immunoglobulin may be an efficient treatment option for patients with late-onset high-grade immune effector cell-associated hematotoxicity refractory to standard therapies

Authors

Institutions

Publication Details

Journal
Haematologica
Published
2025-01-09
DOI
https://doi.org/10.3324/haematol.2024.286714
Primary Topic
CAR-T cell therapy research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

High-dose intravenous immunoglobulin may be an efficient treatment option for patients with late-onset high-grade immune effector cell-associated hematotoxicity refractory to standard therapies

Tsila Zuckerman, Itai Ghersin, Ofrat Beyar‐Katz, Riva Fineman et al.
Haematologica
CAR-T cell therapy research
article

High-dose intravenous immunoglobulin may be an efficient treatment option for patients with late-onset high-grade immune effector cell-associated hematotoxicity refractory to standard therapies

Tsila Zuckerman, Itai Ghersin, Ofrat Beyar‐Katz, Riva Fineman, Eyal Braun, Lilach Bonstein, Yousef Laham, Shimrit Ringelstein‐Harlev, Daniel Kurnik, Noga Setter-Marco, Dana Yehudai-Ofir
article en

Abstract

No abstract available for this paper.
HaematologicaVol. 110(5)
Rambam Health Care Campus (IL)
Pfizer, Teva Pharmaceutical Industries
Good health and well-being
Openalex Percentile: Top 99%
CAR-T cell therapy research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.